Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 728

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 5
Chunk 728
---
-use assets  99   21 Intangible asset  2,039   2,039 Other assets  3   3 TOTAL ASSETS $4,698  $13,043          LIABILITIES AND STOCKHOLDERS' EQUITY        Current Liabilities        Accounts payable and accrued liabilities $1,679  $1,238 Due to related parties  61   30 Operating lease liabilities - current portion  35   23 Total Current Liabilities  1,772   1,291          Operating lease liabilities  69   - TOTAL LIABILITIES  1,841   1,291          STOCKHOLDERS' EQUITY        Preferred Stock, par value $0.001, 416,667 shares authorized,        0 shares issued and outstanding as of December 31, 2024, and 2023  -   - Common Stock, par value $0.001, 50,000,000 shares authorized and        3,281,032 and 3,188,959 shares issued and outstanding as of December 31, 2024, and 2023, respectively  3   3 Additional paid-in capital  53,192   52,262 Accumulated deficit  (50,136)  (40,310)Accumulated other comprehensive loss  (202)  (203)TOTAL STOCKHOLDERS' EQUITY  2,857   11,752          TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $4,698  $13,043 

The accompanying notes are an integral part of these audited consolidated financial statements.

 F-3Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

  Year ended   December 31,   2024  2023        OPERATING EXPENSES      General and administrative $4,115  $4,234 Research and development  5,993   5,696 Total Operating Expenses  10,108   9,930          Loss from Operations  (10,108)  (9,930)         OTHER INCOME